Shots:

• The approval is based on P-III PRIMA study assessing Zejula in patients with newly diagnosed advanced ovarian cancer with complete/partial response to Pt.-based CT regardless of biomarker status
• The therapy is now approved in Canada for monothx. treatment of female adult patients with advanced epithelial ovarian- fallopian tube- or primary peritoneal cancer who are in complete or partial response to 1L Pt.-based CT
• Zejula (PO- qc) is a poly (ADP-ribose) polymerase (PARP) inhibitor and has received approval in 2019- in Canada for recurrent epithelial ovarian- fallopian tube- or primary peritoneal cancer

­ Ref: GSK | Image: GSK